scispace - formally typeset
M

Myron S. Cohen

Researcher at University of North Carolina at Chapel Hill

Publications -  576
Citations -  50913

Myron S. Cohen is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Population & Acquired immunodeficiency syndrome (AIDS). The author has an hindex of 103, co-authored 549 publications receiving 46021 citations. Previous affiliations of Myron S. Cohen include University of Massachusetts Medical School & Scripps Health.

Papers
More filters
Journal ArticleDOI

Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1.

TL;DR: The magnitude of the HIV epidemic has exceeded the worst early predictions and a series of other preventive measures embracing a combination of biological and behavioral approaches have been and are being explored, with some demonstrable positive results.
Journal ArticleDOI

SARS-CoV-2 Variants in Patients with Immunosuppression.

TL;DR: In this article, the authors discuss the challenges of SARS-CoV-2 infection in patients with a weakened immune system, including the potential implications regard to immunosuppression.
Journal ArticleDOI

Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

Raphael J. Landovitz, +65 more
TL;DR: In this paper, safe and effective long-acting injectable agents for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options for preve...
Journal ArticleDOI

Bacterial adaptation to oxidative stress: implications for pathogenesis and interaction with phagocytic cells.

TL;DR: Resistance and adaptation to phagocyte‐derived oxidant stress are critical aspects of bacterial pathogenesis.
Journal ArticleDOI

Breakthrough Pneumococcal Bacteremia in Patients Being Treated with Azithromycin and Clarithromycin

TL;DR: Resistance to macrolides should be considered during the selection of empiric therapy for patients with presumed pneumococcal infections, and low-level resistance tomacrolides can lead to clinical failure, among pneumococci.